An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Phase 2 Completed 325 enrolled Sanofi

RandomizedParallel-groupDouble-blindTreatment

Summary

The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and paroxetine 20 mg once daily in outpatients with generalized anxiety disorder

Timeline

Start: 2006-08
Primary completion: 2008-02
Completion: 2008-02

Publications

Griebel G, Beeske S, Stahl SM. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2012 Nov;73(11):1403-11. doi: 10.4088/JCP.12m07804. Epub 2012 Oct 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NELIVAPTAN	Small molecule	100 mg	Oral
Subject	NELIVAPTAN	Small molecule	250 mg	Oral
Comparator	Paroxetine	Small molecule	20 mg	Oral

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Summary

Timeline

Publications

Drugs

Indications